Telomir Pharmaceuticals, Inc. TELO
1.23
0.02
1.65%
as of 25 Sep
- Market cap
- $83.2M
- P/E
- 0.0×
Follow TELO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
16.14 | 7.00 | 5.14 | 17.51 |
+8 more quarters Free account |
Net Debt/EBITDA |
2.85 | 5.15 | 3.41 | 6.39 | |
Debt/Assets |
2.54% | 3.50% | 0.00% | 0.00% | |
Debt/Equity |
0.03 | 0.04 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.02 | 1.79 | 0.58 | 0.84 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.02) | (0.05) | (0.04) | (0.03) | |
Cash per Share |
0.09 | 0.16 | 0.23 | 0.23 | |
Shareholders Equity per Share |
0.08 | 0.14 | 0.19 | 0.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.08 | 0.14 | 0.19 | 0.22 | |
Free Cash Flow |
(1.01) | (1.77) | (1.20) | (0.93) | |
Working Capital |
5.03 | 4.96 | 5.91 | 6.98 | |
Net Current Asset Value |
5.03 | 4.96 | 5.91 | 6.98 | |
| Other line items | |||||
Quick Ratio |
15.55 | 6.72 | 5.10 | 17.34 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.02) | (0.05) | (0.04) | (0.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.23 | 0.42 | 0.56 | 0.42 | |
Average Assets |
3.10 | 3.14 | 4.33 | 4.22 | |
Average Common Equity |
2.76 | 2.40 | 3.28 | 3.71 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates